United States: Capitol Hill Healthcare Update - February 12, 2018

TRUMP TO RELEASE FISCAL 2019 BUDGET THIS MORNING

The White House this morning is releasing President Trump's fiscal 2019 budget blueprint, which will include funding requests for HHS, FDA, CMS and dozens of other healthcare-related federal agencies.

The White House says the budget will call for $17 billion for opioid-related spending next year, including for HHS' efforts to combat the epidemic by expanding access to prevention, treatment and recovery support services as well as support for mental health.

Trump's budget is only a request of Congress; it doesn't carry the force of law. Many Democrats on Capitol Hill – and even some Republicans – say most of the budget's provisions are unlikely to gain traction in Congress.

SWEEPING BUDGET DEAL INCLUDES KEY HEALTHCARE PROVISIONS

The two-year budget agreement that President Trump signed into law last week not only resolves a series of thorny spending issues that had led to two partial government shutdowns this year, but also includes a series of healthcare provisions affecting programs, providers and beneficiaries.

Major healthcare provisions of the agreement include the following:

  • Doctors' 2019 Medicare fee schedule increase will be reduced by half – from 0.5 percent to .025 percent – cutting payments by $105 million next year and by $1.85 billion over a decade.
  • Pharmaceutical manufacturers will be required to contribute more toward closing the Medicare Part D donut hole – 70 percent, up from the current 50 percent. Although that change would save the government $10 billion because Part D insurance plans' federal subsidies will decrease, the hit to the drug industry could be tens of billions of dollars more. Not every manufacturer has Part D exposure, but one company alone estimated the change could cost $6 billion, while others may have to restate earnings.
  • Manufacturers of generic biologic drugs will join branded biologics in being required to offer Medicare Part D donut hole discounts.
  • A CMS policy linking physicians' quality payment adjustments to Part B drug costs starting in 2019 was repealed.
  • Caps on how much Medicare reimburses for outpatient therapy were permanently repealed.
  • The Children's Health Insurance Program was renewed for an additional four years – for a total of 10 years – up from the six years Congress approved in January.
  • NIH receives an additional $2 billion.
  • Community health centers receive $7 billion.
  • Federal efforts to combat the opioid crisis receive $6 billion.
  • The budget stops Medicaid Disproportionate Share cuts to hospitals for fiscal 2018 and 2019.
  • Wealthier Medicare beneficiaries will see premiums increase by as much as 85 percent.
  • The agreement repeals the Medicare payment cap for therapy services, extends the Special Needs Plans in Medicare Advantage, and authorizes the home health rural add-on payment and the ground ambulance add-on payment.
  • The Affordable Care Act's Independent Payment Advisory Board (IPAB) was repealed. Even though it was never constituted, IPAB was long feared by providers because of its sweeping power to make reimbursement changes with limited ability by Congress to stop them.
  • The underlying budget agreement also includes top-line numbers for how much Congress will spend on the Pentagon and nondefense programs for the next two years. Congress has until March 23 to fill in the details on how each department, agency and program will be funded.

AZAR TO TESTIFY THIS WEEK ON TRUMP'S FISCAL 2019 BUDGET

Even though Alex Azar was confirmed as HHS secretary only late last month and barely had time to contribute to President Trump's fiscal 2019 budget for his department, he will be on Capitol Hill this week defending the budget before three committees.

Azar will testify Wednesday before the House Ways and Means Committee, which has jurisdiction over CMS and Medicare Part A and Part B. He will testify Thursday before the Senate Finance Committee, which has broad legislative jurisdiction over healthcare regulatory and reimbursement policies.

The secretary will testify Thursday before the House Energy and Commerce Health Subcommittee, which has jurisdiction over FDA and Medicare Part B and Part D.

LAWMAKERS URGE FDA CONTROLS ON SERVICING OF MEDICAL DEVICES

Eighteen House lawmakers are urging FDA to impose strict standards on third-party entities that service medical devices.

FDA currently regulates servicing activities performed by the original equipment manufacturer. But the agency doesn't similarly oversee third parties for quality, safety or regulatory controls. The most recent medical device user fee law, enacted last year, required FDA to issue a report on third-party servicing of medical technology.

The lawmakers, led by Reps. Ryan Costello, R-Pa., and Scott Peters, D-Calif., called on FDA to require that all servicing entities register with FDA, report adverse events and establish a quality management system.

McCAIN URGES TRUMP TO BACK BILL FORCING DRUG COMPANIES TO JUSTIFY PRICE INCREASES

Sen. John McCain, R-Ariz., is calling on the White House to get behind his bipartisan legislation that would require pharmaceutical manufacturers to justify price increases.

The legislation, which is co-sponsored by Sen. Tammy Baldwin, R-Wis., would trigger disclosure for drugs whose prices increase more than 10 percent in one year or 25 percent over three years. It also would require companies to release research, manufacturing and marketing expenses related to each drug before any price increase.

The senators sent Trump a letter last week calling on him to support their bill, which was introduced last spring but hasn't attracted support. Companion legislation introduced in the House by Rep. Jan Schakowsky, D-Ill., has eight co-sponsors.

SANDERS: PhRMA CEOs SHOULD TESTIFY ON OPIOID CRISIS

Harkening back to 1994, when tobacco company executives testified before Congress, Sen. Bernie Sanders, I-Vt., said top executives of pharmaceutical companies that manufacture opioids should testify on Capitol Hill.

Sanders sent a letter to Senate HELP Committee Chairman Lamar Alexander, R-Tenn., last week, saying Congress should "summon the courage" and "bring the executives of the pharmaceutical industry before our committee."

Alexander's panel last year held a number of hearings on the opioid epidemic. Last week the committee heard about the crisis' impact on children and families.

Sanders wrote that the committee should determine whether the pharmaceutical industry's marketing practices were complicit in creating the opioid crisis.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions